Immune recovery following switch from EFV-based regimens to bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed immunological non-responders: a 144-week real-world cohort study in China - Quiz - MDSpire

Immune recovery following switch from EFV-based regimens to bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed immunological non-responders: a 144-week real-world cohort study in China

  • By

  • Honghong Yang

  • Qing Yu

  • Mei Li

  • Min Liu

  • June 9, 2026

  • 0 min

Share

Original Source(s)

Immune recovery following switch from EFV-based regimens to bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed immunological non-responders: a 144-week real-world cohort study in China

  • by Honghong Yang, Qing Yu, Mei Li, Min Liu

  • June 9, 2026

Related Content

How the Amish think about vaccines, health care costs, and much more

Incidence and clinical characterization of retinal detachment in acute retinal necrosis: a global federated database analysis

Bundibugyo Ebola without vaccines or therapeutics: why public health fundamentals matter more than border closures